Multi-Cancer Early Detection Market Size, Share & Forecast 2026–2035

Multi-Cancer Early Detection Market by Technology (Liquid Biopsy, Genomic Analysis, Epigenetic & Methylation Analysis, Proteomic Analysis, Multi-Omics Platforms), by Cancer Type (Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Liver Cancer, Ovarian Cancer, Other Cancers), by Sample Type (Blood-Based, Tissue-Based, Urine-Based, Other Sample Types), by End User (Diagnostic Laboratories, Hospitals & Diagnostic Centers, Academic & Research Institutes, Physician Offices), and by Region — Global Industry Perspective, Comprehensive Analysis, and Forecast 2026–2035

St. Catharines, Ontario, October 2026 — Vectomat Insights has published a new report titled ‘Multi-Cancer Early Detection Market by Technology, Cancer Type, Sample Type, End User, and Region — Global Industry Perspective, Comprehensive Analysis, and Forecast 2026–2035.’ The Global Multi-Cancer Early Detection market was valued at USD 1,264.8 Mn in 2025 and is projected to reach USD 5,517.4 Mn by 2035, growing at a CAGR of 15.87% during the forecast period 2026–2035, according to Vectomat Insights.

Liquid biopsy already captures 47.0% of 2025 revenue and is also the fastest-growing technology, while North America holds 37.2% of global spend — and GRAIL's Galleri, backed by an FDA advisory committee in September 2026, sits one regulatory decision away from becoming the first approved multi-cancer screening test in the U.S.

Key Insights Snapshot

What Diagnostics Leaders Need to Know About the Multi-Cancer Early Detection Market

Health-System Chief Medical Officers: An FDA approval for Galleri could land inside the next budget cycle after September 2026's favorable panel vote. Systems without a positive-result navigation pathway — imaging slots, specialist referrals, tissue-of-origin workups — will absorb downstream cost without capturing the stage-shift benefit.

Laboratory Directors: Diagnostic laboratories run 38.8% of 2025 test revenue, but physician offices and academic centers are growing two to three times faster. Labs that don't lock in sequencing capacity and health-system draw-site contracts now risk losing volume as GRAIL alone ran more than 61,000 Galleri tests in Q2 2026.

Payer and Managed Care Executives: The Nancy Gardner Sewell Act, signed in February 2026, opens a Medicare pathway once a test is FDA-approved. Commercial plans that haven't modeled false-positive workup costs against a list price near USD 949 per test will be setting policy on someone else's numbers.

Diagnostics R&D Heads: Liquid biopsy holds 47.0% of revenue and compounds at 19.62%, while standalone multi-omics platforms grow at only 5.34%. Pipelines betting on proteomic add-ons need clinical evidence for pancreatic and ovarian sensitivity, not just headline specificity.

Healthcare Investors: Abbott's acquisition of Exact Sciences closed in March 2026 and Freenome raised about USD 310 Mn in its July 2026 listing. Valuations now hinge on FDA-label wording and Medicare pricing, so binary regulatory risk sits squarely inside a 15.87% CAGR market.

What Is the Multi-Cancer Early Detection Market?

Multi-Cancer Early Detection refers to blood-, urine- and tissue-based tests that look for molecular signals of many cancers at once, often before symptoms appear. Why now? Because the evidence and the money arrived in the same year. GRAIL filed its Galleri premarket approval application in January 2026, an FDA advisory committee backed the test in September, and a new U.S. law gives Medicare a route to pay once a test is approved. Only a handful of cancers have routine screening today, so most deaths still come from tumors nobody looks for. Vectomat Insights values the category at USD 1,264.8 Mn in 2025, rising to USD 5,517.4 Mn by 2035.

How Is the Multi-Cancer Early Detection Market Segmented?

Liquid biopsy owns 47.0% of 2025 revenue — and it's still the fastest-growing technology, compounding at 19.62% a year as single-draw blood tests become the default screening format. By cancer type, lung cancer leads at 22.0% and grows fastest at 21.51%, because a blood test can reach smokers who never book a low-dose CT scan. Blood-based samples hold 69.3% of revenue. Diagnostic laboratories are the largest end user at 38.8%, while academic and research institutes grow fastest as public studies such as the NCI Vanguard Study scale up.

Which Region Leads the Multi-Cancer Early Detection Market?

North America leads with a 37.2% share worth USD 470.5 Mn in 2025, and the U.S. accounts for USD 395.5 Mn of it. That lead rests on laboratory-developed-test flexibility, the deepest pool of developer capital and February 2026's new Medicare coverage law. Asia Pacific is the region to watch: it already holds 25.7% and grows fastest, with South Korea at a 17.9% CAGR and Japan worth USD 98.8 Mn, because insurers there are bundling multi-cancer tests into health plans. Europe holds 25.5%. Latin America (5.3%), Africa (3.2%) and the Middle East (3.1%) are smaller, mostly self-pay markets.

What Is Driving the Multi-Cancer Early Detection Market?

FDA Regulatory Momentum for MCED — GRAIL filed the final module of its Galleri premarket approval application in January 2026, and an FDA advisory committee voted in favor in September 2026 — the first panel ever to back a multi-cancer blood test.

Medicare Coverage Pathway Becomes Law — The Nancy Gardner Sewell Act, signed in February 2026, gives Medicare a route to pay for FDA-approved multi-cancer tests.

Insurer and Channel Partnerships Scale Distribution — Guardant Health launched Shield MCD across several Asian markets with Manulife in March 2026, putting multi-cancer screening inside insurance products.

What Is Restraining the Multi-Cancer Early Detection Market?

Unproven Stage-Shift and Mortality Benefit — NHS-Galleri reduced stage IV diagnoses but missed its primary stage III–IV endpoint at ASCO in June 2026, and payers have noticed.

Self-Pay Pricing and Follow-Up Costs — With Galleri listed at about USD 949, most U.S. testing is still self-pay, and every positive result triggers costly imaging and biopsy.

Despite these challenges, the market is expected to grow from USD 1,264.8 Mn in 2025 to USD 5,517.4 Mn by 2035.

What Industry Leaders Are Saying About the Multi-Cancer Early Detection Market

Report Segmentation & Scope

Who Are the Leading Companies in the Multi-Cancer Early Detection Market?

Key players operating in the Global Multi-Cancer Early Detection market include GRAIL (U.S.), Exact Sciences (U.S.), Guardant Health (U.S.), Freenome (U.S.), Natera (U.S.), Illumina (U.S.), Quest Diagnostics (U.S.), DELFI Diagnostics (U.S.), Harbinger Health (U.S.), Burning Rock Biotech (China), Gene Solutions (Vietnam), GC Genome (South Korea), Mirxes (Singapore), Craif (Japan), among others. It's a market of specialists, not conglomerates — although that's changing fast. Abbott's purchase of Exact Sciences and Illumina's move into proteomics show large diagnostics groups buying their way in. GRAIL holds the regulatory lead after September 2026's favorable FDA panel vote, while Asian developers compete on price and insurer distribution.

What Recent Developments Are Shaping the Multi-Cancer Early Detection Market?

February 2026 — U.S. Congress: The Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act was signed into law, creating a Medicare coverage pathway for FDA-approved multi-cancer tests.

March 2026 — Guardant Health: Launched the Shield MCD multi-cancer detection test in multiple Asian markets through an exclusive partnership with Manulife.

March 2026 — Abbott / Exact Sciences: Abbott completed its acquisition of Exact Sciences, maker of the Cancerguard multi-cancer blood test and Cologuard.

July 2026 — Freenome: Began trading on Nasdaq after its business combination with Perceptive Capital Solutions Corp, with about USD 310 Mn in proceeds.

July 2026 — Gene Solutions: SPOT-MAS 10 multi-cancer screening test received U.S. FDA Breakthrough Device Designation.

September 2026 — GRAIL: An FDA advisory committee voted in favor of approving the Galleri multi-cancer early detection test.

Frequently Asked Questions